Gonadorelin vs hCG

Synthetic GnRH that binds pituitary GnRH receptors; pulsatile dosing stimulates LH/FSH release; used to maintain HPG axis during TRT

Gonadorelin is the synthetic form of endogenous gonadotropin-releasing hormone (GnRH), the hypothalamic decapeptide that drives the pulsatile reproductive axis by stimulating pituitary release of LH and FSH. When delivered in a pulsatile pattern mimicking the hypothalamic pulse generator, gonadorelin effectively restores normal gonadotropin secretion and reproductive function in individuals with hypothalamic hypogonadism. Peer-reviewed clinical studies demonstrate efficacy of pulsatile gonadorelin pump therapy for testosterone restoration in men with congenital hypogonadotropic hypogonadism, as well as for ovulation induction in women with hypothalamic amenorrhea. Gonadorelin is a prescription peptide requiring specialist oversight; continuous rather than pulsatile administration produces paradoxical gonadotropin suppression, making context of use clinically critical. Gonadorelin dosage in TRT support contexts: in men on testosterone replacement therapy, gonadorelin is commonly used off-label to maintain testicular function and endogenous testosterone production capacity. Subcutaneous doses of 100 mcg administered twice weekly are frequently cited in TRT clinical protocols for this purpose — injected at a pulsatile rather than continuous delivery pattern to preserve LH/FSH signaling. This application requires physician supervision due to the dose-timing sensitivity; the paradoxical suppression from continuous dosing is a clinically important consideration that distinguishes gonadorelin from simpler TRT adjuncts. Gonadorelin vs hCG: both are used in men's health contexts to maintain testicular function alongside testosterone therapy, but they act at different levels of the HPG axis. hCG acts directly at the Leydig cell LH receptor to drive testicular testosterone production, bypassing the pituitary. Gonadorelin acts at the pituitary to stimulate endogenous LH and FSH release — preserving the full hypothalamic-pituitary axis rather than just the downstream testosterone signal. The clinical distinction matters for fertility: gonadorelin preserves FSH stimulation of sperm production alongside testosterone, while hCG stimulates testosterone without independently driving FSH. Telehealth hormone therapy providers offering gonadorelin are listed in the PeptideBase directory.

Glycoprotein hormone binding LH receptor on Leydig cells; stimulates testosterone production; prevents testicular atrophy during TRT; maintains spermatogenesis via FSH-like activity

Human chorionic gonadotropin (hCG) is a glycoprotein hormone that acts as a functional analogue of luteinizing hormone (LH), binding to LH receptors on Leydig cells in the testes and granulosa cells in the ovaries to stimulate steroidogenesis. In men, hCG stimulates testicular testosterone production directly, making it a widely used clinical tool for hypogonadotropic hypogonadism, male fertility support, and preservation of testicular function alongside testosterone replacement therapy. Clinical research demonstrates hCG effectiveness for improving testosterone levels and sperm parameters in males with gonadotropin deficiency, as well as for triggering final oocyte maturation in IVF protocols. hCG is an FDA-regulated biologic available in multiple approved formulations; use requires physician supervision due to dose-dependent effects on testosterone, estradiol, and reproductive signaling. hCG dosage in TRT support: in men using testosterone replacement therapy, hCG is prescribed to prevent testicular atrophy and maintain intratesticular testosterone levels needed for spermatogenesis. Typical clinical doses range from 250 to 500 IU subcutaneously administered 2–3 times per week, though protocols vary by provider and individual response. At higher doses, hCG's stimulation of testicular testosterone can also increase aromatization to estradiol — a clinically relevant consideration in TRT management requiring estrogen monitoring. hCG vs gonadorelin: both are used in men's health for testicular preservation alongside TRT, but they act at different axis levels. hCG acts directly on Leydig cell LH receptors, bypassing the pituitary entirely — a direct trophic signal to the testes. Gonadorelin acts upstream at the pituitary to stimulate endogenous LH and FSH release, preserving the full hypothalamic-pituitary-gonadal axis including FSH-driven spermatogenesis. For men prioritizing sperm production, gonadorelin's preservation of FSH signaling offers a potential advantage; for men primarily focused on testicular volume and intratesticular testosterone maintenance, hCG provides a well-validated, direct approach. Telehealth and men's health providers offering hCG and gonadorelin protocols are listed in the PeptideBase directory.